Patient Satisfaction and Visual Symptoms After Wavefront-guided and Wavefrontoptimized LASIK With the WaveLight Platform

PURPOSE: To investigate patient satisfaction and visual symptoms after wavefront-guided LASIK. METHODS: A prospective, randomized, double-masked, controlled study comprised 200 eyes of 100 young patients who underwent LASIK for myopia and astigmatism. Patients were randomly divided into two different treatment groups: standard ablation using wavefront-optimized profiles (wavefront-optimized group) and aberration customized aspheric treatment ablation (customized group) using the WaveLight ALLEGRETTO platform. Patients were asked to complete questionnaires regarding reasons for surgery, satisfaction, and visual symptoms. Patients were followed for 6 months. RESULTS: The most frequent motivating factor for surgery was to improve uncorrected visual acuity (UCVA) in the wavefront-optimized and customized groups (both 100%), followed by freedom from spectacles (86.9% vs 96.3%). At 6 months postoperatively, over 95% of patients in both groups reported their UCVA was as good as anticipated and they were satisfied with the surgery and would recommend the operation to a friend or family member. Satisfaction was not correlated with age, attempted refractive error, residual refractive error, postoperative UCVA, or root-mean-square higher order aberration. The rate of postoperative overall visual symptoms was reduced and the mean analog scores of the symptoms in both groups did not change significantly postoperatively (P > .05). The rate of visual symptoms such as glare (8.7% vs 7.4%), halo (0% vs 7.4%), and night driving difficulty (8.7% vs 3.7%) decreased after LASIK at 6 months postoperatively in the wavefront-optimized and customized groups, respectively. CONCLUSIONS: Patient satisfaction was achieved in young myopic patients who underwent wavefront-guided and standard ("wavefront-optimized") LASIK. The rate of visual symptoms such as glare, halo, and night driving difficulty decreased postoperatively after both treatment protocols.